|Bid||5.80 x 800|
|Ask||5.80 x 1000|
|Day's Range||0.0000 - 0.0000|
|52 Week Range|
|Beta (3Y Monthly)||2.37|
|PE Ratio (TTM)||8.01|
|Earnings Date||Feb 23, 2018 - Mar 5, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||18.00|
Sen. Johnny Isakson, a Georgia Republican, called the Federal Bureau of Investigation in October 2017 to follow up on a complaint lodged by Parker “Pete” Petit, the founder of biomedical company MiMedx Group against an investor who criticized the company and Mr. Petit. Mr. Petit had complained to the FBI and Mr. Isakson called the FBI to ask that they respond to the complaint, his spokeswoman confirmed, adding that Mr. Isakson didn’t request a specific outcome. Seven weeks later, the investor, Marc Cohodes, received a visit from two FBI agents who told him that if he didn’t stop posting negative tweets about Mr. Petit and MiMedx, “there would be consequences,” he told The Wall Street Journal.
NEW YORK, NY / ACCESSWIRE / December 12, 2018 / U.S. equities finished lower on Tuesday after bouncing between the red and green territory. The stocks gained more than 1% across the board on improving ...
Now the actions of the lawmakers could prove embarrassing for them as MiMedx faces possible collapse amid a burgeoning accounting scandal and multiple federal investigations. On Friday, MiMedx said that Ernst & Young, its former auditor, had informed it that “the internal controls necessary for the company to develop reliable financial statements do not exist.” Ernst & Young had been working on a restatement of the company’s earnings since 2012 but resigned last week. MiMedx shares closed Tuesday at $1.54, down from around $18 in January.
The accounting firm was tasked with auditing the company’s financial statements for 2017 and 2018. MiMedx has filed neither its 10-K annual report for 2017 nor its quarterly financial reports for this year. It has said financial reports dating back to 2012 were no longer reliable and would have to be restated.
Buried under the slew of bad news at MiMedx is something of a help wanted ad. The struggling maker of surgical and tissue-graft products announced, among other things, the immediate resignation of its outside auditor.
MARIETTA, Ga., Dec. 5, 2018 /PRNewswire/ -- MiMedx Group, Inc. (OTC PINK: MDXG), a leading developer and marketer of regenerative and therapeutic biologics, today announced that on December 4, 2018, Ernst & Young LLP informed the Company's Audit Committee that it has resigned from the engagement to audit the Company's financial statements for the years ended December 31, 2017 and 2018, effective immediately. MiMedx® is a leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts with patent-protected processes for multiple sectors of healthcare. The Company processes the human placental tissue utilizing its proprietary PURION® process methodology, among other processes, to produce allografts by employing aseptic processing techniques in addition to terminal sterilization.
MARIETTA, Ga., Dec. 5, 2018 /PRNewswire/ -- MiMedx Group, Inc. (OTC PINK: MDXG), a leading developer and marketer of regenerative and therapeutic biologics, today announced certain leadership changes and promotions in conjunction with its plans to implement a broad-based organizational realignment program designed to position the business for long-term success. Additional details regarding the program are available in the Company's press release issued earlier today. "As we continue our efforts to transform our business, we are focused on ensuring that we have the right team and organizational structure in place.
MARIETTA, Ga., Dec. 5, 2018 /PRNewswire/ -- MiMedx Group, Inc. (OTC PINK: MDXG), a leading developer and marketer of regenerative and therapeutic biologics, today announced its plans to implement a broad-based organizational realignment, cost reduction and efficiency program to better ensure the Company's cost structure is appropriate given its revenue expectations. MiMedx plans to execute these initiatives while continuing to deliver products and support for healthcare providers and the patients they serve. "Today's announcement is a continuation of management's efforts to position the business for long-term success by focusing on our wound care business, where our clinical studies best support patient outcomes and for which reimbursement policy has traditionally been more stable," said David Coles, Interim Chief Executive Officer.
New market trends are pushing investors to pay closer attention to the healthcare industry as it has been seen as a safe haven during turbulent times in the broader markets. In fact, according to the "Cognitive Computing and Artificial Intelligence Systems Market in Healthcare" report from ResearchAndMarkets these technologies have gained significant traction. Increased adoption of cognitive and AI platforms can be attributed to their wide application potential across the healthcare industry, including patients and hospitals.
NEW YORK, NY / ACCESSWIRE / November 8, 2018 / U.S. markets advanced on Wednesday as the midterm election results went according to market expectations. The Democrats took over the House, while the Republicans ...
NEW YORK , Nov. 7, 2018 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P MidCap 400 and S&P SmallCap 600: S&P MidCap 400 constituent Jack Henry & Associates Inc. ...
Inc. said Wednesday that the Nasdaq Stock Market will delist its shares and suspend trading in the stock effective Thursday. A formerly highflying maker of tissue grafts and biologic implants used in wound care and sports medicine, MiMedx had warned in July that a Nasdaq delisting was possible. In June, MiMedx said an internal investigation had found that its reported financial results dating back to 2012 were no longer reliable and would have to be restated.
According to MiMedx (NASDAQ:MDXG), its stock will be delisted from Nasdaq at the start of trading tomorrow. The reason for the delisting has to do with the company’s accounting principals not meeting Securities and Exchange Commission (SEC) reporting obligations. The company notes that it doesn’t have any plans to appeal Nasdaq’s decision to delist MiMedx stock from the exchange.
Shares of MiMedx Group Inc. plummeted 34% to pace all Nasdaq losers in morning trade Wednesday, after the biopharmaceutical company disclosed that the Nasdaq will suspend trading in its stock starting Nov. 8, ahead of a delisting. The delisting notice comes as the company has failed to regain compliance with Securities and Exchange Commission reporting obligations amid an internal accounting investigation. Separately, the company said it has adopted a shareholder rights plan, also known as a "poison pill," that becomes exercisable of an investor acquires ownership of 10% or more of MiMedx common stock, in an effort to block an unsolicited buyout attempt. The stock has now lost 67% year to date, while the iShares Nasdaq Biotechnology ETF has gained 2.4% and the S&P 500 has advanced 3.9%.
MARIETTA, Ga., Nov. 7, 2018 /PRNewswire/ -- MiMedx Group, Inc. (MDXG), a leading developer and marketer of regenerative and therapeutic biologics, today announced that its Board of Directors has unanimously authorized the adoption of a limited duration shareholder rights plan (the "Rights Plan") following receipt of notification from The Nasdaq Stock Market LLC ("Nasdaq") indicating that Nasdaq will suspend trading in the Company's stock effective at the open of business on Thursday, November 8, 2018. Charles R. Evans, Chairman of the Board, said, "The Rights Plan provides the Board with appropriate time to make informed decisions that are in the best long-term interests of MiMedx and our shareholders. The Rights Plan was adopted by the Board following evaluation and consultation with the Company's advisors, and is similar to plans adopted by numerous publicly traded companies.
MARIETTA, Ga., Nov. 7, 2018 /PRNewswire/ -- MiMedx Group, Inc. (MDXG), a leading developer and marketer of regenerative and therapeutic biologics, today announced that it has received notification from The Nasdaq Stock Market LLC ("Nasdaq") indicating that, as a result of the interim progress report submitted by the Company on October 31, 2018, the Nasdaq Hearings Panel (the "Panel") has reconsidered the Company's request for continued listing of the Company's common stock on The Nasdaq Capital Market and has determined that Nasdaq will suspend trading in the Company's stock effective at the open of business on Thursday, November 8, 2018.
MARIETTA, Ga. , Nov. 6, 2018 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), a leading developer and marketer of regenerative and therapeutic biologics, today announced that five poster abstracts reporting ...
MARIETTA, Ga. , Oct. 31, 2018 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), a leading developer and marketer of regenerative and therapeutic biologics, today announced that five poster abstracts highlighting ...
Three and a half months after exiting the Atlanta-based biomedical company he founded, MiMedx Group Inc., Pete Petit is preparing for battle. Several other former top MiMedx execs have also left the company. On Sept. 21, MiMedx said it would seek to recover compensation previously paid to four senior MiMedx executives, including Petit.
After all, institutions, mutual funds and their ilk have bureaucratic controls, and clients who can get nervous about a strategy that goes against the grain. Warning! GuruFocus has detected 1 Warning Sign with PVG. One of the greats of the modern short game is Marc Cohodes.
Study Published in International Wound Journal Reported Statistically Significant Evidence of Healing Compared to Standardized Therapy (ST) - Intent-To-Treat (ITT) EpiCord®-Treated Patients = 70% vs ST ...
MiMedx (NASDAQ:MDXG) had a mixed day on Friday that ultimately resulted in a surge as the company is seeking to ameliorate some of its past transgressions. The stock had suffered from the internal probe, which looked into MiMedx’s sales and distribution practices, leading to the indictment of three people who were employed by the Department of Veteran Affairs.